{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T01:10:35Z","timestamp":1789607435105,"version":"build-2803163510"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2016,10,4]],"date-time":"2016-10-04T00:00:00Z","timestamp":1475539200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neth Heart J"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1007\/s12471-016-0905-8","type":"journal-article","created":{"date-parts":[[2016,10,4]],"date-time":"2016-10-04T10:58:04Z","timestamp":1475578684000},"page":"675-681","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["The effect of losartan therapy on ventricular function in Marfan patients with haploinsufficient or dominant negative FBN1 mutations"],"prefix":"10.1007","volume":"24","author":[{"given":"A. W.","family":"den Hartog","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Franken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. P.","family":"van den Berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. H.","family":"Zwinderman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Timmermans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. J.","family":"Scholte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"de Waard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. M.","family":"Spijkerboer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Pals","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. J. M.","family":"Mulder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Groenink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,10,4]]},"reference":[{"key":"905_CR1","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1136\/jmg.2005.039669","volume":"43","author":"PN Robinson","year":"2006","unstructured":"Robinson PN, Arteaga-Solis E, Baldock C, et al. The molecular genetics of Marfan syndrome and related disorders. J Med Genet. 2006;43:769\u201387.","journal-title":"J Med Genet"},{"key":"905_CR2","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1126\/science.1192152","volume":"332","author":"JP Habashi","year":"2011","unstructured":"Habashi JP, Doyle JJ, Holm TM, et\u00a0al. Angiotensin II type 2 receptor signaling attenuates aortic aneurysm in mice through ERK antagonism. Science. 2011;332:361\u20135.","journal-title":"Science"},{"key":"905_CR3","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.jacc.2014.10.050","volume":"65","author":"AW Hartog den","year":"2015","unstructured":"den Hartog AW, Franken R, Zwinderman AH, et\u00a0al. The risk for type B aortic dissection in Marfan syndrome. J\u00a0Am Coll Cardiol. 2015;65:246\u201354.","journal-title":"J Am Coll Cardiol"},{"issue":"12 Suppl 1","key":"905_CR4","doi-asserted-by":"crossref","first-page":"I282","DOI":"10.1161\/hc37t1.094856","volume":"104","author":"H Nagashima","year":"2001","unstructured":"Nagashima H, Sakomura Y, Aoka Y, et\u00a0al. Angiotensin II type 2 receptor mediates vascular smooth muscle cell apoptosis in cystic medial degeneration associated with Marfan\u2019s syndrome. Circulation. 2001;104(12 Suppl 1):I282\u2013I7.","journal-title":"Circulation"},{"key":"905_CR5","doi-asserted-by":"crossref","first-page":"3491","DOI":"10.1093\/eurheartj\/eht334","volume":"34","author":"M Groenink","year":"2013","unstructured":"Groenink M, den Hartog AW, Franken R, et\u00a0al. Losartan reduces aortic dilatation rate in adults with Marfan syndrome: a\u00a0randomized controlled trial. Eur Heart J. 2013;34:3491\u2013500.","journal-title":"Eur Heart J"},{"key":"905_CR6","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1093\/eurheartj\/ehv151","volume":"36","author":"O Milleron","year":"2015","unstructured":"Milleron O, Arnoult F, Ropers J, et al. Marfan Sartan: a\u00a0randomized, double-blind, placebo-controlled trial. Eur Heart J. 2015;36:2160\u20136.","journal-title":"Eur Heart J"},{"key":"905_CR7","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1056\/NEJMoa1404731","volume":"371","author":"RV Lacro","year":"2014","unstructured":"Lacro RV, Dietz HC, Sleeper LA, et\u00a0al. Atenolol versus losartan in children and young adults with Marfan\u2019s syndrome. N Engl J Med. 2014;371:2061\u201371.","journal-title":"N Engl J Med"},{"key":"905_CR8","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1136\/heartjnl-2011-300169","volume":"97","author":"P Witte de","year":"2011","unstructured":"de Witte P, Aalberts JJ, Radonic T, et\u00a0al. Intrinsic biventricular dysfunction in Marfan syndrome. Heart. 2011;97:2063\u20138.","journal-title":"Heart"},{"key":"905_CR9","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.gene.2013.10.033","volume":"534","author":"JJ Aalberts","year":"2014","unstructured":"Aalberts JJ, van Tintelen JP, Meijboom LJ, et al. Relation between genotype and left-ventricular dilatation in patients with Marfan syndrome. Gene. 2014;534:40\u20133.","journal-title":"Gene"},{"key":"905_CR10","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.ijcard.2005.10.010","volume":"112","author":"JF Backer de","year":"2006","unstructured":"de Backer JF, Devos D, Segers P, et\u00a0al. Primary impairment of left ventricular function in Marfan syndrome. Int J Cardiol. 2006;112:353\u20138.","journal-title":"Int J Cardiol"},{"key":"905_CR11","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.amjcard.2004.11.042","volume":"95","author":"LJ Meijboom","year":"2005","unstructured":"Meijboom LJ, Timmermans J, van Tintelen JP, et\u00a0al. Evaluation of left ventricular dimensions and function in Marfan\u2019s syndrome without significant valvular regurgitation. Am J Cardiol. 2005;95:795\u20137.","journal-title":"Am J Cardiol"},{"key":"905_CR12","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1093\/eurjhf\/hfq127","volume":"12","author":"F Alpendurada","year":"2010","unstructured":"Alpendurada F, Wong J. Kiotsekoglou a\u00a0et\u00a0al. Evidence for Marfan cardiomyopathy. Eur J Heart Fail. 2010;12:1085\u201391.","journal-title":"Eur J Heart Fail"},{"key":"905_CR13","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1745-6215-11-3","volume":"11","author":"T Radonic","year":"2010","unstructured":"Radonic T, de Witte P, Baars MJ, Zwinderman AH, Mulder BJ, Groenink M. Losartan therapy in adults with Marfan syndrome: study protocol of the multi-center randomized controlled COMPARE trial. Trials. 2010;11:3.","journal-title":"Trials"},{"key":"905_CR14","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1002\/(SICI)1096-8628(19960424)62:4<417::AID-AJMG15>3.0.CO;2-R","volume":"62","author":"A Paepe de","year":"1996","unstructured":"de Paepe A, Devereux RB, Dietz HC, Hennekam RC, Pyeritz RE. Revised diagnostic criteria for the Marfan syndrome. Am J Med Genet. 1996;62:417\u201326.","journal-title":"Am J Med Genet"},{"issue":"7","key":"905_CR15","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1136\/jmg.2009.072785","volume":"47","author":"BL Loeys","year":"2010","unstructured":"Loeys BL, Dietz HC, Braverman AC, et\u00a0al. The revised Ghent nosology for the Marfan syndrome. J\u00a0Med Genet. 2010;47(7):476\u201385.","journal-title":"J Med Genet"},{"issue":"15","key":"905_CR16","doi-asserted-by":"crossref","first-page":"e523","DOI":"10.1161\/CIRCULATIONAHA.108.190748","volume":"118","author":"RO Bonow","year":"2008","unstructured":"Bonow RO, Carabello BA, Chatterjee K, et\u00a0al. Focused update incorporated into the ACC\/AHA 2006 guidelines for the management of patients with valvular heart disease: a\u00a0report of the American College of Cardiology\/American Heart Association task force on practice guidelines (writing committee to revise the 1998 guidelines for the management of patients with valvular heart disease): endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation. 2008;118(15):e523\u2013e661.","journal-title":"Circulation"},{"key":"905_CR17","doi-asserted-by":"publisher","unstructured":"Franken R, den Hartog AW, Radonic T, et\u00a0al. Beneficial outcome of Losartan therapy depends on type of FBN1 mutation in Marfan syndrome. Circ Cardiovasc Genet. 2015;383\u20138. doi: 10.1161\/CIRCGENETICS.114.000950","DOI":"10.1161\/CIRCGENETICS.114.000950"},{"key":"905_CR18","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1471-2350-2-11","volume":"2","author":"W Liu","year":"2001","unstructured":"Liu W, Schrijver I, Brenn T, Furthmayr H, Francke U. Multi-exon deletions of the FBN1 gene in Marfan syndrome. BMC Med Genet. 2001;2:11.","journal-title":"BMC Med Genet"},{"key":"905_CR19","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1006\/geno.1993.1349","volume":"17","author":"HC Dietz","year":"1993","unstructured":"Dietz HC, McIntosh I, Sakai LY, et al. Four novel FBN1 mutations: significance for mutant transcript level and EGF-like domain calcium binding in the pathogenesis of Marfan syndrome. Genomics. 1993;17:468\u201375.","journal-title":"Genomics"},{"key":"905_CR20","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1172\/JCI117930","volume":"95","author":"DM Milewicz","year":"1995","unstructured":"Milewicz DM, Grossfield J, Cao SN, Kielty C, Covitz W, Jewett T. A\u00a0mutation in FBN1 disrupts profibrillin processing and results in isolated skeletal features of the Marfan syndrome. J\u00a0Clin Invest. 1995;95:2373\u20138.","journal-title":"J Clin Invest"},{"key":"905_CR21","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1056\/NEJM199007193230303","volume":"323","author":"DW Hollister","year":"1990","unstructured":"Hollister DW, Godfrey M, Sakai LY, Pyeritz RE. Immunohistologic abnormalities of the microfibrillar-fiber system in the Marfan syndrome. N Engl J Med. 1990;323:152\u20139.","journal-title":"N Engl J Med"},{"key":"905_CR22","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1086\/341581","volume":"71","author":"I Schrijver","year":"2002","unstructured":"Schrijver I, Liu W, Odom R, et\u00a0al. Premature termination mutations in FBN1: distinct effects on differential allelic expression and on protein and clinical phenotypes. Am J Hum Genet. 2002;71:223\u201337.","journal-title":"Am J Hum Genet"},{"key":"905_CR23","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1086\/302582","volume":"65","author":"I Schrijver","year":"1999","unstructured":"Schrijver I, Liu W, Brenn T, Furthmayr H, Francke U. Cysteine substitutions in epidermal growth factor-like domains of fibrillin-1: distinct effects on biochemical and clinical phenotypes. Am J Hum Genet. 1999;65:1007\u201320.","journal-title":"Am J Hum Genet"},{"key":"905_CR24","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1080\/10976640500295516","volume":"7","author":"LE Hudsmith","year":"2005","unstructured":"Hudsmith LE, Petersen SE, Francis JM, Robson MD, Neubauer S. Normal human left and right ventricular and left atrial dimensions using steady state free precession magnetic resonance imaging. J\u00a0Cardiovasc Magn Reson. 2005;7:775\u201382.","journal-title":"J Cardiovasc Magn Reson"},{"key":"905_CR25","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1006\/mgme.2000.3032","volume":"71","author":"PJ Lijnen","year":"2000","unstructured":"Lijnen PJ, Petrov VV, Fagard RH. Induction of cardiac fibrosis by transforming growth factor-beta(1). Mol Genet Metab. 2000;71:418\u201335.","journal-title":"Mol Genet Metab"},{"key":"905_CR26","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.yjmcc.2010.10.033","volume":"51","author":"M Dobaczewski","year":"2011","unstructured":"Dobaczewski M, Chen W, Frangogiannis NG. Transforming growth factor (TGF)-beta signaling in cardiac remodeling. J Mol Cell Cardiol. 2011;51:600\u20136.","journal-title":"J Mol Cell Cardiol"},{"key":"905_CR27","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1161\/01.CIR.0000020689.12472.E0","volume":"106","author":"F Kuwahara","year":"2002","unstructured":"Kuwahara F, Kai H, Tokuda K, et al. Transforming growth factor-beta function blocking prevents myocardial fibrosis and diastolic dysfunction in pressure-overloaded rats. Circulation. 2002;106:130\u20135.","journal-title":"Circulation"},{"key":"905_CR28","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw116","author":"P Blyszczuk","year":"2016","unstructured":"Blyszczuk P, Muller-Edenborn B, Valenta T, et al. Transforming growth factor-beta-dependent Wnt secretion controls myofibroblast formation and myocardial fibrosis progression in experimental autoimmune myocarditis. Eur Heart J. 2016; doi: 10.1093\/eurheartj\/ehw116 .","journal-title":"Eur Heart J"},{"key":"905_CR29","doi-asserted-by":"crossref","first-page":"2959","DOI":"10.1161\/CIRCULATIONAHA.105.584623","volume":"112","author":"Y Rikitake","year":"2005","unstructured":"Rikitake Y, Oyama N, Wang CY, et al. Decreased perivascular fibrosis but not cardiac hypertrophy in ROCK1+\/- haploinsufficient mice. Circulation. 2005;112:2959\u201365.","journal-title":"Circulation"},{"key":"905_CR30","first-page":"1329","volume":"124","author":"JR Cook","year":"2014","unstructured":"Cook JR, Carta L, Benard L, et\u00a0al. Abnormal muscle mechanosignaling triggers cardiomyopathy in mice with Marfan syndrome. J\u00a0Clin Invest. 2014;124:1329\u201339.","journal-title":"J Clin Invest"},{"key":"905_CR31","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1161\/01.HYP.36.5.747","volume":"36","author":"YM Pinto","year":"2000","unstructured":"Pinto YM, Pinto-Sietsma SJ, Philipp T, et al. Reduction in left ventricular messenger RNA for transforming growth factor beta(1) attenuates left ventricular fibrosis and improves survival without lowering blood pressure in the hypertensive TGR(mRen2)27 Rat. Hypertension. 2000;36:747\u201354.","journal-title":"Hypertension"}],"container-title":["Netherlands Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12471-016-0905-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12471-016-0905-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12471-016-0905-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,14]],"date-time":"2019-09-14T03:39:43Z","timestamp":1568432383000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12471-016-0905-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,4]]},"references-count":31,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["905"],"URL":"https:\/\/doi.org\/10.1007\/s12471-016-0905-8","relation":{},"ISSN":["1568-5888","1876-6250"],"issn-type":[{"value":"1568-5888","type":"print"},{"value":"1876-6250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,4]]}}}